Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors

Cancer

Volumn 121, Issue 11, 2015, Pages 1817-1826

  Abu Khalaf, Maysa M ^a   Baumgart, Megan A ^b   Gettinger, Scott N ^a   Doddamane, Indukala ^a   Tuck, David P ^c   Hou, Shihe ^d   Chen, Nianhang ^d   Sullivan, Catherine ^a   Lezon Geyda, Kimberly ^a   Zelterman, Daniel ^a   Hatzis, Christos ^a   Deshpande, Hari ^a   Digiovanna, Michael P ^a   Azodi, Masoud ^a   Schwartz, Peter E ^a   Harris, Lyndsay N ^e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c EMD SERONO INC   (United States)

^d CELGENE CORPORATION   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

mammalian target of rapamycin (mTOR); nanoparticle albumin bound paclitaxel (nab paclitaxel); sirolimus; solid tumors; 18F fludeoxyglucose positron emission tomography (FDG PET)

Indexed keywords

CHOLESTEROL; FLUORODEOXYGLUCOSE F 18; PACLITAXEL; PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; TAXANE DERIVATIVE; TENSIN; ALBUMINOID; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; NANOPARTICLE; TARGET OF RAPAMYCIN KINASE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EDEMA; ENDOMETRIUM CANCER; ENZYME ACTIVATION; FATIGUE; FEMALE; GENE EXPRESSION PROFILING; HEAD AND NECK CANCER; HEADACHE; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPOXIA; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MELANOMA; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUROPATHY; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVARY CANCER; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PRURITUS; RASH; SMALL CELL LUNG CANCER; SOLID TUMOR; SWEAT GLAND DISEASE; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; NEOPLASMS; PROCEDURES; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; AGED; ALBUMIN-BOUND PACLITAXEL; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NANOPARTICLES; NEOPLASMS; PACLITAXEL; POSITRON-EMISSION TOMOGRAPHY; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84929653684     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29254     Document Type: Article

References (32)

1. Faivre S, Kroemer G, Raymond E,. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006; 5: 671-688.
2. Rowinsky EK,. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol. 2004; 16: 564-575.
3. Chan S,. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer. 2004; 91: 1420-1424.
4. Fingar DC, Blenis J,. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004; 23: 3151-3171.
5. Marks AR,. Sirolimus for the prevention of in-stent restenosis in a coronary artery. N Engl J Med. 2003; 349: 1307-1309.
6. Cohen EE, Wu K, Hartford C, et al., Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012; 18: 4785-4793.
7. Spencer CM, Faulds D,. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs. 1994; 48: 794-847.
8. Rowinsky EK, Donehower RC,. Paclitaxel (taxol). N Engl J Med. 1995; 332: 1004-1014.
9. Von Hoff DD, Ervin T, Arena FP, et al., Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369: 1691-1703.
10. Ibrahim NK, Samuels B, Page R, et al., Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005; 23: 6019-6026.
11. Socinski MA, Bondarenko I, Karaseva NA, et al., Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012; 30: 2055-2062.
12. Gradishar WJ, Tjulandin S, Davidson N, et al., Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23: 7794-7803.
13. Gradishar WJ, Krasnojon D, Cheporov S, et al., Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival. Clin Breast Cancer. 2012, 12, 313-321.
14. Mondesire WH, Jian W, Zhang H, et al., Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004; 10: 7031-7042.
15. VanderWeele D, Zhou R, Rudin C,. Akt upregulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther. 2004; 3: 1605-1613.
16. Faried LS, Faried A, Kanuma T, et al., Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Eur J Cancer. 2006; 42: 934-947.
17. Kaplan B, Meier-Kriesche HU, Kahan BD,. A limited sampling strategy for estimating sirolimus area-under-the-concentration curve. Clin Chem. 1997; 43: 539-540.
18. Camp RL, Chung GG, Rimm DL,. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002; 8: 1323-1327.
19. Smyth GK,. Limma: linear models for microarray data. In:, Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, eds. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. New York, NY: Springer; 2005: 397-420.
20. Majumder PK, Febbo PG, Bikoff R, et al., mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004; 10: 594-601.
21. O'Reilley, Rojo F, She QB, et al., mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006; 66: 1500-1508.
22. Whiteman EL, Cho H, Birnbaum MJ,. Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab. 2002; 13: 444-451.
23. Elstrom RL, Bauer DE, Buzzai M, et al., Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004; 64: 3892-3899.
24. Weber WA, Petersen V, Schmidt B, et al., Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003; 21: 2651-2657.
25. Young H, Baum R, Cremerius U, et al., Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999; 35: 1773-1782.
26. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003; 39: 2012-2020.
27. Chen JL, Appelbaum DE, Kocherginsky M, et al., FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med. 2013; 2: 545-552.
28. Guba M, Koehl GE, Neppl E, et al., Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int. 2005; 18: 89-94.
29. Peralba JM, DeGraffenried L, Friedrichs W, et al., Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res. 2003; 9: 2887-2892.
30. Ellard SL, Clemons M, Gelmon KA, et al., Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009; 27: 4536-4541.
31. Shafer A, Zhou C, Gehrig PA, Boggess JF, Bae-Jump VL,. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int J Cancer. 2010; 126: 1144-1154.
32. Ball HG, Blessing J, Lentz S, et al., A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1996; 62: 278-281.